Hims & Hers Health, Inc. Class A Common Stock (HIMS)
27.23
+0.28 (1.04%)
NYSE · Last Trade: Apr 18th, 5:47 PM EDT
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.
Via The Motley Fool · April 17, 2025
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.
Via StockStory · April 17, 2025
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that trade tariffs could add upward pressure to inflation in the short term and complicate the Fed's efforts to stabilize the economy. He warned that such trade measures are "likely to move us further away from our goals," referring to the Fed's dual mandate of price stability and maximum employment.
Via StockStory · April 16, 2025
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?
Via MarketBeat · April 10, 2025
Based on technical and fundamental analysis of NYSE:HIMS we find: HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock and is consolidating.
Via Chartmill · April 10, 2025
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff actions, welcomed the pause as a sign of a more measured path forward.
Via StockStory · April 9, 2025
Via The Motley Fool · April 2, 2025
Via Benzinga · April 2, 2025
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it.
Via Investor's Business Daily · April 2, 2025
Via Benzinga · April 2, 2025
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07.
Via Benzinga · April 1, 2025
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug.
Via Stocktwits · April 1, 2025
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its platform, marking a significant expansion beyond its previous focus on lower-cost alternatives to Novo Nordisk's Wegovy. This move positioned the company to tap into the growing demand for weight loss solutions and attract a broader customer base. The company added, "As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience."
Via StockStory · April 1, 2025
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.
Via Benzinga · April 1, 2025
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform.
Via Investor's Business Daily · April 1, 2025
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.
Via MarketBeat · April 1, 2025
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Via StockStory · March 31, 2025
This high-growth stock may be cheaper than you think.
Via The Motley Fool · March 29, 2025
Via The Motley Fool · March 28, 2025
There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.
Via The Motley Fool · March 24, 2025
Via Benzinga · March 19, 2025
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug Administration raised concerns about unapproved GLP-1 drugs used for weight loss, including versions (compounded) prescribed by Hims & Hers. There had been growing market demand for weight loss drugs in recent months, and they've evolved to be a significant driver of sales growth for manufacturers and distributors. The FDA's concerns could indicate tighter regulatory scrutiny, which restricts the ability of suppliers like Hims & Hers to get the affected versions to consumers.
Via StockStory · March 18, 2025